TP53AIP1 Antibody

What is TP53AIP1 and what is its biological significance?

TP53AIP1 (Tumor protein p53-regulated apoptosis-inducing protein 1) is a critical protein involved in p53-mediated apoptotic responses. It is induced by p53 following phosphorylation on Ser-46 and plays a significant role in cellular apoptosis pathways. The expression of TP53AIP1 is directly regulated by p53, and ectopic expression of TP53AIP1 can lead to apoptotic cell death . This protein has been identified as having tumor suppressor properties in several cancer types, most notably breast cancer, where patients with lower TP53AIP1 expression demonstrate reduced survival rates compared to those with higher expression levels . The biological significance of TP53AIP1 lies in its role as a downstream mediator of p53-dependent apoptosis, making it an important target for cancer research and potential therapeutic development.

What are the basic characteristics of commercially available TP53AIP1 antibodies?

Commercially available TP53AIP1 antibodies typically present the following characteristics:

These antibodies are typically generated against synthetic peptides from the amino terminus of human TP53AIP1, with the immunogen often located within the first 50 amino acids of the protein .

How does TP53AIP1 function in normal cellular processes versus cancer pathology?

In normal cellular processes, TP53AIP1 serves as a critical mediator in the p53 apoptotic pathway. When DNA damage or cellular stress occurs, p53 becomes phosphorylated on Ser-46, which then induces TP53AIP1 expression. This activation is facilitated by p53DINP1, highlighting the regulatory network controlling apoptotic responses . Once expressed, TP53AIP1 contributes to mitochondrial-mediated apoptotic cell death, allowing elimination of damaged cells that might otherwise pose a cancer risk.

In cancer pathology, TP53AIP1 expression is frequently dysregulated, often showing decreased levels compared to normal tissues. Research indicates that breast cancer tissues exhibit significantly reduced TP53AIP1 expression compared to adjacent non-tumor tissues . This downregulation correlates with poorer patient outcomes, suggesting TP53AIP1 functions as a tumor suppressor. When experimentally overexpressed in breast cancer cell lines (MDA-MB-415 and MDA-MB-468), TP53AIP1 inhibits cell viability, induces G0/G1 cell cycle arrest, and promotes apoptosis . These anti-cancer effects operate through multiple mechanisms, including regulation of apoptosis-related proteins (increased Bax, cleaved caspase-3/9, decreased Bcl-2), cell cycle factors, and inhibition of the PI3K/Akt signaling pathway .

What are the optimal working conditions for TP53AIP1 antibody in different experimental applications?

The optimal working conditions for TP53AIP1 antibody vary based on the specific application:

Western Blot (WB):

• Recommended concentration: 4-8 μg/mL

• Optimized for human samples, particularly cancer cell lines

• Sample preparation should include protease inhibitors

• Detection systems: Both chemiluminescence and fluorescence-based systems are compatible

• Expected molecular weight: ~68 kDa (observed)

Immunocytochemistry (ICC):

• Recommended concentration: Starting at 10 μg/mL, with optimization advised

• Fixation: 4% paraformaldehyde followed by permeabilization

• Blocking: 5-10% normal serum from the same species as the secondary antibody

• Incubation: Overnight at 4°C for primary antibody

• Validated in human cell lines such as HL60

Immunofluorescence (IF):

• Recommended concentration: Starting at 20 μg/mL

• Similar protocol to ICC with emphasis on reduced autofluorescence

• Secondary antibody selection: Fluorophore-conjugated anti-rabbit IgG

• Counterstaining: DAPI for nuclear visualization

• Has been successfully implemented in HL60 cells

ELISA:

• Working dilution must be determined empirically

• Standard curve generation using recombinant TP53AIP1 is recommended for quantitative analysis

• Both direct and sandwich ELISA formats are compatible

Regardless of application, researchers should perform preliminary titration experiments to determine optimal antibody concentration for their specific experimental conditions and sample types.

How can researchers effectively validate TP53AIP1 antibody specificity in their experimental systems?

To ensure robust and reproducible results, researchers should implement a comprehensive validation strategy for TP53AIP1 antibodies:

• Positive and negative control samples:

  • Positive controls: Cell lines with confirmed TP53AIP1 expression (e.g., HL60 cells)

  • Negative controls: Cell lines with TP53AIP1 knockdown using siRNA/shRNA

  • Tissue controls: Compare tumor tissues with adjacent normal tissues

• Molecular weight verification:

  • Confirm band detection at the expected molecular weight (~68 kDa observed vs. 12.9 kDa calculated)

  • Account for potential post-translational modifications or protein complexes that may affect migration

• Peptide competition assay:

  • Pre-incubate antibody with the immunizing peptide before application

  • Signal should be significantly reduced or eliminated if the antibody is specific

• Multiple antibody validation:

  • Use antibodies from different vendors or those targeting different epitopes

  • Consistent results across different antibodies strengthen specificity claims

• Genetic validation approaches:

  • CRISPR/Cas9 knockout of TP53AIP1

  • Overexpression systems with tagged TP53AIP1 constructs

  • These approaches provide definitive controls for antibody validation

• Cross-reactivity assessment:

  • Test antibody against related family members or proteins with similar domains

  • Especially important when working with novel cell lines or tissues

• Application-specific validation:

  • For immunostaining techniques: Include secondary-only controls

  • For IP: Include control IgG to identify non-specific binding

Proper validation not only ensures experimental reliability but also facilitates accurate interpretation of results, particularly in complex experimental systems or when investigating TP53AIP1 in previously uncharacterized contexts.

What methodological approaches are recommended for investigating TP53AIP1's role in the p53-mediated apoptotic pathway?

To comprehensively investigate TP53AIP1's role in p53-mediated apoptosis, researchers should consider the following methodological approaches:

• Expression correlation studies:

  • Analyze TP53AIP1 and p53 expression using qRT-PCR and western blotting

  • Assess phosphorylation status of p53 at Ser-46 using phospho-specific antibodies

  • Correlate TP53AIP1 expression with p53 activation following DNA damage

• Manipulation of TP53AIP1 expression:

  • Overexpression studies using transgenic technology in relevant cell lines

  • Knockdown/knockout approaches using siRNA, shRNA, or CRISPR/Cas9

  • Inducible expression systems to control timing of TP53AIP1 expression

• Apoptosis assessment techniques:

  • Flow cytometry with Annexin V/PI staining to quantify apoptotic cells

  • TUNEL assay for DNA fragmentation

  • Measurement of mitochondrial membrane potential

  • Caspase activity assays (particularly caspase-3 and caspase-9)

• Cell cycle analysis:

  • PI staining and flow cytometry to determine cell cycle distribution

  • BrdU incorporation assays for S-phase analysis

  • Expression analysis of cell cycle regulators (e.g., p21, cyclins)

• Protein interaction studies:

  • Co-immunoprecipitation to identify TP53AIP1 binding partners

  • Proximity ligation assay for in situ protein interaction detection

  • Yeast two-hybrid or mammalian two-hybrid assays for interaction screening

• Signaling pathway analysis:

  • Western blotting for PI3K/Akt pathway components and phosphorylation status

  • Inhibitor studies to determine pathway dependencies

  • Reporter assays for transcriptional activities

• In vivo approaches:

  • Xenograft models with TP53AIP1-manipulated cancer cells

  • Patient-derived xenografts to assess clinical relevance

  • Correlation of TP53AIP1 expression with patient outcomes in clinical samples

These methodologies provide a comprehensive framework for investigating TP53AIP1's functional role within the p53-mediated apoptotic pathway, enabling researchers to establish mechanistic insights and potential therapeutic implications.

What are the most common technical challenges when working with TP53AIP1 antibodies and how can they be addressed?

Researchers frequently encounter several technical challenges when working with TP53AIP1 antibodies. Here are the most common issues and recommended solutions:

• Molecular Weight Discrepancy:

  • Challenge: Observed molecular weight (~68 kDa) differs significantly from calculated weight (~12.9 kDa)

  • Solution: This discrepancy may reflect post-translational modifications, alternative splicing, or protein complexes. Use positive control lysates with confirmed TP53AIP1 expression. Consider denaturing conditions that disrupt protein complexes if investigating the monomeric form.

• Low Signal Intensity:

  • Challenge: Weak detection in Western blot or immunostaining applications

  • Solution: Optimize antibody concentration (start with 4-8 μg/mL for WB, 10 μg/mL for ICC, 20 μg/mL for IF) . Extend primary antibody incubation time (overnight at 4°C). Use signal enhancement systems like biotin-streptavidin amplification or tyramide signal amplification for low-abundance targets.

• High Background:

  • Challenge: Non-specific staining obscuring specific signals

  • Solution: Increase blocking stringency (5-10% normal serum or BSA). Extend blocking time to 2 hours. Include 0.1-0.3% Triton X-100 in washing buffers. Consider using more dilute antibody concentration with longer incubation times.

• Multiple Bands in Western Blot:

  • Challenge: Detection of multiple bands making interpretation difficult

  • Solution: TP53AIP1 exists in three isoforms that may be detected simultaneously . Use higher percentage gels (12-15%) for better resolution. Perform peptide competition assays to identify specific versus non-specific bands. Consider using alternative lysate preparation methods to reduce protein degradation.

• Inconsistent Immunostaining:

  • Challenge: Variable staining patterns across experiments

  • Solution: Standardize fixation protocols (duration, temperature). Optimize antigen retrieval methods. Prepare fresh antibody dilutions for each experiment. Use automated staining platforms if available.

• Storage and Stability Issues:

  • Challenge: Antibody performance degradation over time

  • Solution: Store antibody at recommended temperatures (4°C for three months, -20°C for up to one year) . Avoid repeated freeze-thaw cycles. Consider aliquoting antibody upon receipt. Add stabilizing proteins (0.1% BSA) if not already present in commercial formulation.

• Cross-Reactivity Concerns:

  • Challenge: Potential non-specific binding to related proteins

  • Solution: Validate specificity using knockout/knockdown controls. Test antibody in multiple applications to confirm consistent results. Consider using monoclonal antibodies for highest specificity if polyclonal antibodies show cross-reactivity.

Proper documentation of optimization steps and standardization of protocols across experiments will help ensure consistent and reliable results when working with TP53AIP1 antibodies.

How can researchers optimize protocols for detecting TP53AIP1 in different cancer cell lines and tissue samples?

Optimizing protocols for TP53AIP1 detection across diverse cancer models requires systematic adaptation of standard methods. Here are comprehensive guidelines:

For Cancer Cell Lines:

• Sample Preparation Optimization:

  • Cell lysis buffer selection: For nuclear proteins like TP53AIP1, use RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors

  • Sonication: Brief sonication (3-5 pulses) may improve extraction of nuclear proteins

  • Protein concentration: Standardize to 20-40 μg for Western blotting, adjust based on expression levels

• Western Blot Protocol Refinements:

  • Gel percentage: 10-12% for optimal resolution around 68 kDa (observed MW)

  • Transfer conditions: Semi-dry transfer (25V, 30 minutes) or wet transfer (30V overnight at 4°C)

  • Blocking: 5% non-fat milk or BSA in TBST for 1-2 hours

  • Primary antibody incubation: 4-8 μg/mL at 4°C overnight

  • Detection system: ECL-based systems with varying sensitivity tiers depending on expression level

• Immunocytochemistry/Immunofluorescence Adaptations:

  • Fixation method: 4% PFA (15 minutes) for structural proteins; methanol fixation (-20°C, 10 minutes) as alternative

  • Permeabilization: 0.2% Triton X-100 for 10 minutes

  • Antibody concentration: Start at 10-20 μg/mL and titrate as needed

  • Detection amplification: Consider tyramide signal amplification for low-expressing lines

For Tissue Samples:

• Tissue Processing Considerations:

  • Fixation: 10% neutral buffered formalin, 24-48 hours (shorter for smaller samples)

  • Embedding: Paraffin embedding with controlled temperature to preserve epitopes

  • Sectioning: 4-5 μm sections for optimal antibody penetration

  • Storage: Freshly cut sections perform better than stored slides

• Antigen Retrieval Methods:

  • Heat-induced epitope retrieval: Citrate buffer (pH 6.0) or TE buffer (pH 9.0)

  • Pressure cooker method: 5 minutes at high pressure often yields superior results

  • Enzymatic retrieval: Proteinase K treatment (1-5 minutes) as alternative approach

• IHC Protocol Optimization:

  • Endogenous peroxidase blocking: 3% H₂O₂ for 10 minutes

  • Protein blocking: 5-10% normal serum or commercial blocking solutions

  • Primary antibody dilution: Begin at 1:50-1:500 range and optimize

  • Incubation conditions: Overnight at 4°C in humidified chamber

  • Detection systems: Polymer-based detection systems often provide cleaner background than ABC methods

Cell Line/Tissue-Specific Adaptations:

• For breast cancer research:

  • Cell lines: MDA-MB-415 and MDA-MB-468 have been successfully used for TP53AIP1 studies

  • Compare with normal breast epithelial cells as controls

  • Consider analyzing matched patient tumor/normal pairs

• For p53 status considerations:

  • Determine p53 mutation status of cell lines/tissues

  • Wild-type p53 cell lines may show inducible TP53AIP1 expression following DNA damage

  • Mutant p53 cell lines may require exogenous TP53AIP1 expression for functional studies

• Expression induction strategies:

  • For low-expressing lines, consider treatment with DNA-damaging agents (doxorubicin, cisplatin)

  • p53 reactivation (using MDM2 inhibitors like Nutlin-3) in wild-type p53 cells

  • Demethylating agents if epigenetic silencing is suspected

By systematically optimizing these parameters for specific research models, investigators can achieve reliable and reproducible detection of TP53AIP1 across diverse cancer cell lines and tissue samples.

What approaches should be used to analyze discrepancies between observed and predicted molecular weights of TP53AIP1?

The significant discrepancy between the observed molecular weight of TP53AIP1 (approximately 68 kDa) and its predicted weight (approximately 12.9 kDa) requires systematic investigation. Researchers should consider the following analytical approaches:

• Comprehensive Isoform Analysis:

  • Bioinformatic assessment of known TP53AIP1 isoforms

  • RT-PCR using isoform-specific primers to identify expressed variants

  • Cloning and expression of individual isoforms with epitope tags

  • The presence of three reported isoforms may contribute to size variations

• Post-Translational Modification Analysis:

  • Phosphorylation assessment: Treat lysates with phosphatases prior to SDS-PAGE

  • Glycosylation evaluation: Use deglycosylation enzymes (PNGase F, O-glycosidase)

  • Ubiquitination analysis: Immunoprecipitate TP53AIP1 and probe for ubiquitin

  • SUMOylation investigation: Detect SUMO modifications using anti-SUMO antibodies

• Protein Complex Analysis:

  • Native PAGE compared with denaturing conditions

  • Crosslinking experiments to stabilize protein complexes

  • Size exclusion chromatography to separate protein complexes

  • Blue native PAGE followed by second-dimension SDS-PAGE

• Technical Validation Approaches:

  • Multiple antibody validation: Test antibodies targeting different epitopes

  • Recombinant protein expression: Compare migration of tagged recombinant protein

  • Mass spectrometry confirmation: Excise the 68 kDa band and perform protein identification

  • CRISPR/Cas9 knockout: Generate knockout cells to confirm band specificity

• Sample Preparation Variables:

  • Test different lysis buffers (RIPA, NP-40, urea-based)

  • Evaluate various reducing agent concentrations

  • Compare fresh vs. frozen samples

  • Assess different heating conditions (time and temperature) prior to loading

• Experimental Protocol Considerations:

  • Sample multiple cell lines for consistent pattern of migration

  • Use gradient gels (4-20%) to improve resolution

  • Include molecular weight markers flanking the range of interest

  • Compare reducing and non-reducing conditions

• Comprehensive Reporting:

  • Document experimental conditions thoroughly

  • Report both observed and predicted molecular weights

  • Include positive controls with known migration patterns

  • Present multiple experimental approaches to confirm findings

This systematic approach allows researchers to characterize the nature of the molecular weight discrepancy and ensure accurate interpretation of experimental results. Understanding these differences is essential for proper validation of antibody specificity and accurate identification of TP53AIP1 in experimental systems.

How can researchers effectively design experiments to study TP53AIP1's role in cancer progression and therapeutic resistance?

Designing rigorous experiments to investigate TP53AIP1's role in cancer progression and therapeutic resistance requires multifaceted approaches:

• Expression Correlation Studies:

  • Methodology: Analyze TP53AIP1 expression in paired tumor/normal tissues across cancer stages

  • Technical approach: Implement tissue microarrays with immunohistochemistry

  • Data analysis: Correlate expression with clinicopathological features and survival outcomes

  • Validation: Confirm protein expression patterns using multiple antibodies and transcript analysis

  • Clinical relevance: Extend findings to patient databases (TCGA, METABRIC) for survival correlation as demonstrated in breast cancer studies

• Functional Modulation Experiments:

  • Gain-of-function studies:

    • Stable expression systems using lentiviral/retroviral vectors

    • Inducible expression systems (Tet-On/Off) for temporal control

    • Transient transfection for acute effects assessment

  • Loss-of-function approaches:

    • siRNA/shRNA knockdown (validated sequences)

    • CRISPR/Cas9 knockout with multiple guide RNAs

    • Dominant-negative mutants

  • Readouts: Cell viability, proliferation, apoptosis, cell cycle distribution, invasion/migration

• Therapeutic Resistance Models:

  • Drug resistance development:

    • Generate resistant cell lines through gradual drug exposure

    • Measure TP53AIP1 expression changes during resistance acquisition

  • Sensitization studies:

    • Overexpress TP53AIP1 in resistant lines to assess re-sensitization

    • Combine with conventional therapies (chemotherapy, radiation)

  • Pathway analysis:

    • Investigate PI3K/Akt pathway modulation as demonstrated in breast cancer models

    • Analyze apoptotic pathway proteins (Bax, Bcl-2, cleaved caspases)

• In Vivo Experimental Approaches:

  • Xenograft models:

    • Subcutaneous implantation of TP53AIP1-modified cancer cells

    • Orthotopic models for tissue-specific microenvironment

  • Patient-derived xenografts:

    • Correlate TP53AIP1 expression with treatment response

    • Test TP53AIP1-targeting strategies in PDX models

  • Genetic mouse models:

    • Tissue-specific TP53AIP1 knockout/overexpression

    • Combine with oncogene activation/tumor suppressor inactivation

• Mechanistic Investigations:

  • p53 dependency:

    • Compare effects in p53 wild-type versus mutant/null backgrounds

    • Analyze Ser-46 phosphorylation status and correlation with TP53AIP1 expression

  • Apoptosis pathway:

    • Mitochondrial function assessment (membrane potential, cytochrome c release)

    • Caspase activation cascade (focus on caspase-9 and caspase-3)

  • Cell cycle regulation:

    • Detailed analysis of G0/G1 arrest mechanisms observed in breast cancer models

    • Key regulator expression (p21, cyclins, CDKs)

• Translational Research Design:

  • Biomarker development:

    • Validate TP53AIP1 as predictor of therapy response

    • Develop IHC scoring systems for clinical application

  • Therapeutic targeting:

    • Design approaches to enhance TP53AIP1 expression

    • Test combination with p53 reactivating therapies

  • Clinical trial correlatives:

    • Include TP53AIP1 analysis in treatment studies

    • Stratify patients based on expression levels

These approaches provide a comprehensive framework for investigating TP53AIP1's role in cancer, with potential to identify new therapeutic strategies and predictive biomarkers.

What are the critical considerations for interpreting TP53AIP1 expression patterns in different cancer tissues?

Accurate interpretation of TP53AIP1 expression patterns in cancer tissues requires careful consideration of multiple biological and technical factors:

By systematically addressing these considerations, researchers can generate more reliable and clinically relevant interpretations of TP53AIP1 expression patterns across different cancer tissues.

How can researchers integrate TP53AIP1 analysis with broader cancer signaling pathway investigations?

Integrating TP53AIP1 analysis within comprehensive cancer signaling network investigations requires strategic experimental design and data integration approaches:

• PI3K/Akt Pathway Integration:

  • Experimental approach: Analyze TP53AIP1 overexpression effects on PI3K and Akt phosphorylation status

  • Technical methodology:

    • Western blot for phospho-PI3K (p-PI3K), total PI3K, phospho-Akt (p-Akt), and total Akt

    • Quantify phosphorylation ratios relative to total protein

  • Mechanistic investigation:

    • Use specific PI3K inhibitors (LY294002, wortmannin) to determine pathway dependency

    • Assess feedback mechanisms through time-course experiments

  • Functional correlation:

    • Link pathway suppression to apoptotic responses and cell cycle arrest

    • Quantify MDM2 expression changes as downstream readout

• p53 Signaling Network Analysis:

  • Upstream regulation:

    • Analyze p53DINP1 expression and its correlation with TP53AIP1 induction

    • Investigate Ser-46 phosphorylation dynamics using phospho-specific antibodies

  • Downstream effects:

    • Multiplex analysis of p53 target genes (p21, PUMA, NOXA, BAX)

    • Chromatin immunoprecipitation to identify p53 binding at TP53AIP1 promoter

  • Integrated approaches:

    • Implement p53 pathway-focused arrays before/after TP53AIP1 modulation

    • Use CRISPR screens to identify synthetic lethal interactions

• Apoptotic Pathway Integration:

  • Intrinsic pathway components:

    • Measure Bax/Bcl-2 ratio changes following TP53AIP1 modulation

    • Analyze mitochondrial membrane potential and cytochrome c release

  • Execution phase analysis:

    • Quantify cleaved caspase-9 and cleaved caspase-3 activation kinetics

    • Implement caspase activity assays for functional confirmation

  • Systems approach:

    • Apply apoptosis inhibitors to determine pathway dependencies

    • Utilize protein interaction studies to identify direct binding partners

• Cell Cycle Regulatory Network:

  • G0/G1 arrest mechanisms:

    • Analyze cyclin D1, CDK4/6 expression following TP53AIP1 overexpression

    • Quantify p21 induction as potential mediator of cell cycle arrest

  • S-phase entry regulation:

    • Measure BrdU incorporation to quantify DNA synthesis

    • Analyze E2F transcriptional activity using reporter assays

  • Integrated cell cycle analysis:

    • Synchronize cells to determine phase-specific effects

    • Implement FUCCI system for live-cell cycle visualization

• Multi-Omics Integration Strategies:

  • Transcriptomic profiling:

    • RNA-seq before/after TP53AIP1 modulation to identify gene expression networks

    • Pathway enrichment analysis to determine affected signaling cascades

  • Proteomic approaches:

    • Phosphoproteomics to identify altered signaling nodes

    • Interaction proteomics (IP-MS) to map TP53AIP1 protein complexes

  • Epigenomic integration:

    • ChIP-seq for histone modifications at TP53AIP1-regulated genes

    • DNA methylation analysis of TP53AIP1 promoter in various cancer types

• Systems Biology Approaches:

  • Network modeling:

    • Construct protein-protein interaction networks centered on TP53AIP1

    • Implement Boolean network models of integrated pathways

  • Pathway perturbation analysis:

    • Combine targeted inhibitors with TP53AIP1 modulation

    • Identify synergistic and antagonistic pathway interactions

  • Computational prediction:

    • Use machine learning to predict TP53AIP1 interactors

    • Develop predictive models of therapy response based on TP53AIP1 status

• Translational Research Integration:

  • Therapeutic combination studies:

    • Test TP53AIP1 modulation with conventional therapies

    • Identify synthetic lethal interactions for targeted approaches

  • Biomarker development:

    • Correlate TP53AIP1 expression with therapy response

    • Develop multivariate predictive models incorporating pathway activation status

  • Clinical sample analysis:

    • Implement multiplex immunohistochemistry for simultaneous pathway visualization

    • Validate findings in patient-derived organoids or xenografts

These integrated approaches provide a comprehensive framework for positioning TP53AIP1 within the broader context of cancer signaling networks, potentially revealing new therapeutic targets and biomarkers for clinical application.